Brooks Laboratories Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 16, 2026

Key Highlights

The Latest Trading Price of Brooks Laboratories Ltd is ₹ 46.72 as of 15 May 15:30 . The P/E Ratio of Brooks Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Corona Remedies Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Brooks Laboratories Ltd changed from ₹ 153.53 crore on March 2021 to ₹ 317.37 crore on March 2025 . This represents a CAGR of 15.63% over 5 yearsThe Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Brooks Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 21.89 crore. This represent the decline of -100% The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The ebitda of Brooks Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 6.05 crore. This represent the decline of -100% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The net profit of Brooks Laboratories Ltd changed from ₹ -2.41 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The Dividend Payout of Brooks Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Brooks Laboratories Ltd

Brooks Laboratories Limited was incorporated on January 23, 2002.
The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment.
It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes.
At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Brooks Laboratories Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Brooks Laboratories Ltd or Corona Remedies Ltd?

Market cap of Brooks Laboratories Ltd is 137 Cr while Market cap of Corona Remedies Ltd is 10,880 Cr

What are the key factors driving the stock performance of Brooks Laboratories Ltd and Corona Remedies Ltd?

The stock performance of Brooks Laboratories Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Brooks Laboratories Ltd and Corona Remedies Ltd?

As of May 16, 2026, the Brooks Laboratories Ltd stock price is INR ₹46.72. On the other hand, Corona Remedies Ltd stock price is INR ₹1779.1.

How do dividend payouts of Brooks Laboratories Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Brooks Laboratories Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.